Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisNovartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group's continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 124,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

(Photo: http://photos.prnewswire.com/prn
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- Market Research Report ... 2009-2019 is a professional and in-depth market ... industry. The report firstly reviews the basic ... application and manufacturing technology. The report then ... Oxybutynin Hydrochloride listing their product specification, capacity, ...
(Date:9/19/2014)... 2014 Research and ... addition of the "Global Gynecological Devices ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... into wide categories based on their operations. ... of different gynecological conditions that affect the ...
(Date:9/19/2014)... , September 19, 2014 ... Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture ... Users (Hospitals), Advanced technologies - Global Forecast to ... is poised to reach $19,786.3 Million by 2019 ... of 6.8% from 2014 to 2019. ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2011 on Monday, May 9, 2011. A press release announcing ... trading. (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the first quarter ended March ...
... Measuring the body temperatures of newborns with temporal artery ... by axillary (under arm) thermometry, the clinically recommended method ... to a new study reported in Advances in ... first published clinical analysis evaluating the accuracy of temporal ...
Cached Medicine Technology:Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011 2Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011 3Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns 2Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns 3
(Date:9/20/2014)... Winston-Salem, NC (PRWEB) September 20, 2014 The excitement ... held in Mount Airy, North Carolina. This year the Surry ... that draws people from around the country who are still fans ... Griffith Show is a sitcom that aired on CBS from 1960 ... 9th best show in American television history. Mount Airy, North ...
(Date:9/20/2014)... 2014 Plumbing construction services ... 5, indicating a moderately favorable purchasing environment for buyers. ... current and future pricing trends that will limit the ... factors that negatively affect buyer power are a lack ... the moderate switching costs. Buyers benefit, however, from low ...
(Date:9/20/2014)... 20, 2014 Final Cut Pro X ... release of the Information theme for FCPX filmmakers. , “Fun, ... describe the Information theme,” says Christina Austin, CEO of Pixel ... so professional.” , Information features easy to use controls that ... the environment. Change the background color, color of each circle ...
(Date:9/20/2014)... Nevada (PRWEB) September 20, 2014 ... extremely successful showing at the PAIN Week conference ... Cosmopolitan Hotel and Casino in Las Vegas from ... MarijuanaDoctors.com primarily attended PAIN Week in the hopes ... as a viable and legitimate tool to treat ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 “Copay coupons,” ... sales of brand drugs among patients with prescription drug ... according to a new report from the Department ... General (OIG). Federal anti-kickback laws prohibit suppliers from offering ... by the federal government. , The report highlights that ...
Breaking Medicine News(10 mins):Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2
... Unit in Leeds receives Lilly,s 2008 Global ... ... Inc. (NYSE:,CVD), a leading provider of drug development services, today announced ... Lilly and Company., Covance,s clinical research unit based in Leeds, ...
... According to recent,reporting, including today,s Washington ... is circulating a draft proposed,regulation that, if ... providers to withhold the critical health care ... about their care. As a leading health,care ...
... Data for Second ... Quarter 2008 ... July 31 Sunrise Senior Living,Inc. (NYSE: SRZ ) today announced that ... the Securities and Exchange Commission,("SEC"). The Company also reported preliminary selected financial and,operating ...
... in chronic kidney cases , , THURSDAY, July 31 (HealthDay ... routinely measured marker of bone disease -- may signal ... for chronic kidney disease, say U.S. researchers. , The ... a three-year period. It found that patients with alkaline ...
... Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical company ... that it will release financial results for the ... market open on Friday, August 8, 2008., ... Gregory Frost,PhD, Vice President and Chief Scientific Officer, ...
... WEST CHESTER, Ohio, July 31 AtriCure, Inc.,(Nasdaq: ATRC ), ... today announced that it will present at the following,investor conferences during ... August 6, 2008 at the Millennium Broadway ... and Chief Executive Officer, is scheduled to present at 9:00 ...
Cached Medicine News:Health News:Covance Recognized for Outstanding Customer Service by Eli Lilly and Company 2Health News:SPOKESPERSON AVAILABILTY: Planned Parenthood President Available for Interviews on Proposed HHS Regulations 2Health News:Sunrise Files 2007 Form 10-K 2Health News:Sunrise Files 2007 Form 10-K 3Health News:Sunrise Files 2007 Form 10-K 4Health News:Sunrise Files 2007 Form 10-K 5Health News:Sunrise Files 2007 Form 10-K 6Health News:Sunrise Files 2007 Form 10-K 7Health News:Sunrise Files 2007 Form 10-K 8Health News:Sunrise Files 2007 Form 10-K 9Health News:Sunrise Files 2007 Form 10-K 10Health News:Sunrise Files 2007 Form 10-K 11Health News:Bone Disease Test Shows Death Risk for Dialysis Patients 2Health News:Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8 2Health News:AtriCure to Present at the BMO Focus on Healthcare and Canaccord Adams Global Growth Conferences in August 2
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
The Trilogy system builds on the success of the Harris/Galante Porous and HGP II cups by combining proven features with new technology designed to inhibit the formation and migration of polyethylene ...
The Secur-Fit cups incorporate enhancements derived from years of clinical, radiographic, and implant retrieval observations....
The Bofor acetabular revision cup addresses cases of severe acetabular destruction....
Medicine Products: